NCVTC to develop of host-directed antivirals for COVID 19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ ncvtc-developing-antiviral-serb-supporting-project
Antivirals are believed to have fewer tendencies in inducing drug resistance said Dr Naveen Kumar from NCVTC

The Science and Engineering Research Board (SERB) has approved support for a study by the National Centre for Veterinary Type Cultures (NCVTC), ICAR-NRC from Hisar in Haryana, which will screen their library of 94 small molecule chemical inhibitors for antivirals against coronaviruses.

The molecules are known to inhibit cellular kinases, phosphatases, and epigenetic regulators such as histone methyl transferase, histone deacetylase, and DNA methyl transferase. The targets of these inhibitors are well characterized in cancer, however, their role in the virus life cycle is not known. The selected candidates (hits) with anti-coronavirus activity will be subjected to study their molecular mechanism of action, besides examining generation of potential drug-resistant virus variants.

Classically, antiviral drugs are developed by directly targeting certain viral proteins. However, this strategy often fails due to the rapid generation of drug-resistant viruses. Unlike higher organisms, a viral polymerase-the viral enzyme that synthesizes its nucleic acid (RNA) does not have proofreading capacity. Therefore, RNA viruses such as the coronaviruses do not have the mechanisms to remove wrongly incorporated nucleotides (building blocks of viral RNA) during the synthesis of the viral genome. The lack of proofreading capacity results in the accumulation of point mutations in the viral genome. This leads to changes in viral proteins. The altered viral proteins may then become resistant to the available antiviral drugs. This intriguing ability of the viruses to rapidly and frequently change themselves is a big challenge for the scientists in developing antiviral drugs.

Viruses can only replicate inside the host cell. A host (human) cell contains around 25,000 proteins. During replication, viruses establish numerous interactions with these cellular proteins. A virus needs more than 1000 different cellular proteins to replicate inside the host cell effectively.

"Chemical library screening in medicinal chemistry research is a useful methodology that considerably shortens drug discovery and development cycle, especially for newly identified etiologic agents, such as SARS-Cov-2. Such approach provides for rapid access to useful pharmacophores and narrows down the search for preferred molecular scaffolds and is also compatible with high-throughput robotic assays. While supporting Cov-2 vaccine development programs, it is also imperative to have sufficient focus toward anti-coronavirus drug discovery pipeline," said Prof Sandeep Verma, Secretary, SERB.

Dr. Naveen Kumar, scientist NCVTC is exploring an alternate strategy to target such cellular proteins, protein-protein (virus-host) interaction, or epigenetic regulators for antiviral drug development commonly called as host-directed antiviral therapy. The host-directed antivirals are believed to have fewer tendencies in inducing drug resistance because it is not possible for the virus to easily change missing cellular functions by mutations. In addition, host-directed antiviral agents are likely to exert broad-spectrum antiviral effects because the requirement of host factors by viruses is usually conserved across the members of a particular virus family or sometimes even across the members of different virus families. The institute’s collection of small molecule inhibitors will be the resource from which Dr. Kumar hopes to find his antiviral weapon targeting cellular proteins, protein-protein (virus-host) interaction, or epigenetic regulators for COVID 19.

Tags : #NCVTC #SERB #Antiviral #FightCorona #VaccineNews #COVID-19

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026